Results 111 to 120 of about 6,425 (142)

Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis. [PDF]

Dis Markers, 2021
Guo G, Huang A, Huang X, Xu T, Yao L.
europepmc   +1 more source

The role of soluble suppression of tumorigenicity 2 in pulmonary hypertension: a systematic review and meta-analysis. [PDF]

Am Heart J Plus
Cao L, Teng W, Sang L, Xu X.
europepmc   +1 more source

Correlation between Levels of Serum Lipoprotein-Associated Phospholipase A2 and Soluble Suppression of Tumorigenicity 2 and Condition of Acute Heart Failure Patients and Their Predictive Value for Prognosis. [PDF]

J Healthc Eng, 2021
Zhang J, Wang L, Zhao Z, Li L, Xia Y.
europepmc   +1 more source

A Simple and Cost-Effective Electrochemical Assay for Heart Failure Prognosis Using Soluble Suppression of Tumorigenicity 2‑Specific Nanobodies. [PDF]

ACS Pharmacol Transl Sci
Sirimanakul S, Hurley JD, Vutipow N, Loison F, Kasorn A, Tabtimmai L, Riangrungroj P, Leelawattanachai J, Ananwattanasuk T, Swainson N, Choowongkomon K, Kruse AC, Waraho-Zhmayev D.   +12 more
europepmc   +1 more source

Dual and context-dependent role of the interleukin-33/soluble suppression of tumorigenicity 2 axis in obesity and adipose tissue inflammation. [PDF]

Mol Med
Casado M, Gómez-Ambrosi J, Ramírez B, Becerril S, Rodríguez A, Valentí V, Moncada R, Silva C, Escalada J, Frühbeck G, Catalán V.   +10 more
europepmc   +1 more source

Impact of Midregional N-Terminal Pro-Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treated With Catheter Ablation for Atrial Fibrillation: The Biorhythm Study. [PDF]

J Am Heart Assoc, 2021
Badoz M, Serzian G, Favoulet B, Sellal JM, De Chillou C, Hammache N, Laurent G, Mebazaa A, Ecarnot F, Bardonnet K, Seronde MF, Schiele F, Meneveau N.   +12 more
europepmc   +1 more source

NSTEMI Risk Prediction with the Combination of the Biomarkers Epicardial Adipose Tissue and Soluble Suppression of Tumorigenicity 2. [PDF]

Med Sci Monit
Yin J, Qiu B, Li T, Tao Y, Gu X.
europepmc   +1 more source

Soluble Suppression of Tumorigenicity 2 (sST2) as a Diagnostic and Prognostic Marker in Acute Heart Failure and Sepsis: A Comparative Analysis. [PDF]

Diagnostics (Basel)
Davini F, Fogolari M, D'Avanzo G, Ristori MV, Nucciarelli S, Bani L, Cristiano A, De Cesaris M, Spoto S, Angeletti S.   +9 more
europepmc   +1 more source

Lack of prognostic significance for major adverse cardiac events of soluble suppression of tumorigenicity 2 levels in patients with ST-segment elevation myocardial infarction. [PDF]

Cardiol J, 2021
Kim M, Lee DI, Lee JH, Kim SM, Lee SY, Hwang KK, Kim DW, Cho MC, Bae JW.   +8 more
europepmc   +1 more source

Reference interval and the role of soluble suppression of tumorigenicity 2 (sST2) in subclinical cardiac dysfunction at health checkups. [PDF]

J Clin Lab Anal, 2020
Nah EH, Cho S, Kim S, Cho HI.
europepmc   +1 more source